A human APOC3 missense variant and monoclonal antibody accelerate apoC-III clearance and lower triglyceride-rich lipoprotein levels-Reference-Cited by-同舟云学术

A human APOC3 missense variant and monoclonal antibody accelerate apoC-III clearance and lower triglyceride-rich lipoprotein levels

Published:2017-08-21 Issue:9 Volume:23 Page:1086-1094
ISSN:1078-8956
Container-title:Nature Medicine
language:en
Short-container-title:Nat Med

Author:

Khetarpal Sumeet A,Zeng Xuemei,Millar John S,Vitali Cecilia,Somasundara Amritha Varshini Hanasoge,Zanoni Paolo,Landro James A,Barucci Nicole,Zavadoski William J,Sun Zhiyuan,de Haard Hans,Toth Ildikó V,Peloso Gina M,Natarajan Pradeep,Cuchel Marina,Lund-Katz Sissel,Phillips Michael C,Tall Alan R,Kathiresan Sekar,DaSilva-Jardine Paul,Yates Nathan A,Rader Daniel J

Publisher

Springer Science and Business Media LLC

Subject

General Biochemistry, Genetics and Molecular Biology,General Medicine

Link

http://www.nature.com/articles/nm.4390.pdf

Reference53 articles.

1. Musunuru, K. & Kathiresan, S. Surprises from genetic analyses of lipid risk factors for atherosclerosis. Circ. Res. 118, 579–585 (2016).

2. Khetarpal, S.A., Qamar, A., Millar, J.S. & Rader, D.J. Targeting ApoC-III to reduce coronary disease risk. Curr. Atheroscler. Rep. 18, 54 (2016).

3. Jørgensen, A.B., Frikke-Schmidt, R., Nordestgaard, B.G. & Tybjærg-Hansen, A. Loss-of-function mutations in APOC3 and risk of ischemic vascular disease. N. Engl. J. Med. 371, 32–41 (2014).

4. Crosby, J. et al. Loss-of-function mutations in APOC3, triglycerides, and coronary disease. N. Engl. J. Med. 371, 22–31 (2014).

5. Pollin, T.I. et al. A null mutation in human APOC3 confers a favorable plasma lipid profile and apparent cardioprotection. Science 322, 1702–1705 (2008).

Cited by 95 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. A novel lncRNA GM47544 modulates triglyceride metabolism by inducing ubiquitination-dependent protein degradation of APOC3;Molecular Metabolism;2024-10

2. The U-shaped association between remnant cholesterol and risk of all-cause and cardiovascular deaths in diabetic adults: Findings from NHANES 1999–2018;Nutrition, Metabolism and Cardiovascular Diseases;2024-10

3. Recent progress in gene therapy for familial hypercholesterolemia treatment;iScience;2024-09

4. Human genetic variation determines 24-hour rhythmic gene expression and disease risk;2024-08-05

5. Instrumental variable and colocalization analyses identify endotrophin and HTRA1 as potential therapeutic targets for coronary artery disease;iScience;2024-07